Pancreatic Neuroendocrine Neoplasms exhibit coupled genomic, epigenetic, and immune evolution, shaping therapeutic vulnerability.

Advanced Pancreatic Neuroendocrine Neoplasms (PanNENs) remain largely incurable despite advances in surgery, targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT). Immune checkpoint blockade has shown limited and inconsistent benefit, highlighting a critical gap in understanding tumor immunology. PanNENs are highly heterogeneous, with well-differentiated PanNETs and poorly differentiated PanNECs following distinct evolutionary paths. This paper addresses how differentiation state and lineage programs serve as major organizing principles, influencing immune contexture and therapeutic vulnerabilities.

Researchers synthesized findings from recent genomic, epigenomic, and immune profiling studies on Pancreatic Neuroendocrine Neoplasms (PanNENs). They analyzed existing data to propose a conceptual model where genomic alterations, epigenetic states, and immune architectures evolve as a coupled system. The study distinguished between well-differentiated PanNETs and poorly differentiated PanNECs, detailing their unique molecular and immune landscapes. The authors aimed to outline biologically rational, precision-guided therapeutic strategies based on these integrated insights.

The study found that PanNETs are typically defined by chromatin regulatory alterations, relative lineage stability, and weakly inflamed immune microenvironments, though a subset shows increased tumor-associated macrophage infiltration linked to aggressive disease. By contrast, PanNECs are characterized by lineage instability, cell-cycle dysregulation, and a more inflamed yet functionally suppressed immune context. This includes greater immune-cell infiltration and more frequent checkpoint pathway engagement. However, this inflammation often coexists with impaired antigen presentation, including human leukocyte antigen class I loss, tumor-intrinsic immune evasion, and suppressive myeloid networks, preventing effective antitumor immunity. The core finding is:

Genomic alterations, epigenetic states, and immune architectures evolve as a coupled system in PanNENs, with lineage identity shaping antigen presentation defects, immune suppression, and therapeutic vulnerability.